# IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

> **NCT03515512** · PHASE1 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 23 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia

## Interventions

- **DRUG:** Enasidenib

## Key facts

- **NCT ID:** NCT03515512
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-17
- **Primary completion:** 2021-12-31
- **Final completion:** 2023-02-13
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03515512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03515512, "IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03515512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*